AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15191514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, clarithromycin and tinidazole (both dosing regimens)
Number of subjects: 205
Study 11753827 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of secondary prophylaxis against cytomegalovirus (CMV)
Number of subjects: 36
Study 11753827 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 36
Study 9834046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg 4 times a day) for 10 days with concomitant clarithromycin (500 mg twice a day) from days 6 through 10
Number of subjects: 12
Study 9834046 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice a day) for 10 days combined with cisapride (10 mg 4 times a day) from days 6 through 10
Number of subjects: 12
Study 9834046 — intervention group
Group type: COMPARATOR
Intervention: Cisapride (10 mg 4 times a day)
Number of subjects: 12
Study 9834046 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (500 mg twice a day)
Number of subjects: 12
Study 9706623 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin 150 mg/kg/day
Number of subjects: 28
Study 9706623 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin 65-75 mg/kg/day
Number of subjects: 28
Study 9706623 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (both dosages)
Number of subjects: 28
Study 9706623 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (responders)
Number of subjects: 28
Study 9706623 — intervention group
Group type: COMPARATOR
Intervention: ACTH (in non-responders)
Number of subjects: 28
Study 9706623 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid (in non-responders)
Number of subjects: 28
Study 9706623 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam (in non-responders)
Number of subjects: 28
Study 9706623 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG (last visit)
Number of subjects: 28
Study 9706623 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 28
Study 1885830 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytrimethylene carbonate (Maxon)
Number of subjects: 584
Study 1885830 — intervention group
Group type: COMPARATOR
Intervention: Polyglactic acid (Vicryl)
Number of subjects: 584
Study 6859570 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 2 mg
Number of subjects: 40
Study 6859570 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 5 mg
Number of subjects: 40
Study 6859570 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 7.5 mg
Number of subjects: 40
Study 6859570 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 7.5 mg
Number of subjects: 40
Study 31595302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 22
Study 31595302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30571289 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT-treadmill
Number of subjects: 16
Study 30571289 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT-stepper
Number of subjects: 16
Study 30571289 — intervention group
Group type: COMPARATOR
Intervention: MCT-treadmill
Number of subjects: 16
Study 28214664 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening during blood draw skill practice
Number of subjects: 73
Study 28214664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 73
Study 26805940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous hysteropexy
Number of subjects: 208
Study 26805940 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy with suspension of the uterosacral ligaments
Number of subjects: 208
Study 26805940 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 208
Study 24456991 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-D supplementation
Number of subjects: 104
Study 22537824 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (ever vs. never)
Number of subjects: 1676
Study 22537824 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1 shared-epitope (SE) alleles
Number of subjects: 1676
Study 22537824 — intervention group
Group type: EXPERIMENTAL
Intervention: SE-positive smokers
Number of subjects: 1676
Study 22537824 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between smoking and SE alleles
Number of subjects: 1676
Study 22537824 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*04:05 SE allele
Number of subjects: 1676
Study 22537824 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking and SE alleles combination
Number of subjects: 1676
Study 20167988 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive therapy with valganciclovir (n=36)
Number of subjects: 70
Study 20167988 — intervention group
Group type: COMPARATOR
Intervention: Valacyclovir prophylaxis (n=34)
Number of subjects: 70
Study 17414805 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise hypotension (PEH)
Number of subjects: 10
Study 17414805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) induced hypotension
Number of subjects: 10
Study 17414805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor (CP) during PEH
Number of subjects: 10
Study 17414805 — intervention group
Group type: COMPARATOR
Intervention: Resting baseline
Number of subjects: 10
Study 15858814 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus stimulation (n=11)
Number of subjects: 19
Study 15858814 — intervention group
Group type: COMPARATOR
Intervention: Optimized pharmacological treatment (n=8)
Number of subjects: 19
Study 11932658 — intervention group
Group type: EXPERIMENTAL
Intervention: MIVS technique
Number of subjects: 20
Study 11932658 — intervention group
Group type: COMPARATOR
Intervention: Conventional open repair
Number of subjects: 20
Study 9147710 — intervention group
Group type: EXPERIMENTAL
Intervention: Egifilin 200 mg retard tablet
Number of subjects: 26
Study 9147710 — intervention group
Group type: EXPERIMENTAL
Intervention: Egifilin 400 mg retard tablet
Number of subjects: 26
Study 8372753 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammography and physical examination (for women 40-49 years old)
Number of subjects: 0
Study 8372753 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammography and physical examination (for women 50-59 years old)
Number of subjects: 0
Study 8372753 — intervention group
Group type: COMPARATOR
Intervention: Usual care after an initial physical examination (for women 40-49 years old)
Number of subjects: 0
Study 8372753 — intervention group
Group type: COMPARATOR
Intervention: Annual physical examination only (for women 50-59 years old)
Number of subjects: 0
Study 3555852 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine and lecithin combination
Number of subjects: 16
Study 3555852 — intervention group
Group type: COMPARATOR
Intervention: Lecithin alone
Number of subjects: 16
Study 3555852 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 16
Study 3555852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29883807 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration with unstable shoes
Number of subjects: 59
Study 29883807 — intervention group
Group type: COMPARATOR
Intervention: Whole body vibration with standard shoes
Number of subjects: 59
Study 25845833 — intervention group
Group type: EXPERIMENTAL
Intervention: Wish group (positive intervention)
Number of subjects: 124
Study 25845833 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 124
Study 24439980 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 928
Study 24439980 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 928
Study 22884040 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 129
Study 22884040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 22884040 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment group
Number of subjects: 129
Study 20972285 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF (locally produced energy-dense supplement)
Number of subjects: 96
Study 20972285 — intervention group
Group type: COMPARATOR
Intervention: HCCM (High Calorie Cereal Milk)
Number of subjects: 96
Study 18333868 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 900 mg
Number of subjects: 0
Study 18333868 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (active comparator)
Number of subjects: 0
Study 18333868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18333868 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (all doses)
Number of subjects: 0
Study 18333868 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (up to 2363 ng ml(‐1))
Number of subjects: 0
Study 16122484 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate suction (suction overnight and water seal during the day)
Number of subjects: 94
Study 16122484 — intervention group
Group type: COMPARATOR
Intervention: Water seal alone
Number of subjects: 94
Study 12741449 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients with duodenal ulcer (DU)
Number of subjects: 0
Study 12741449 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients with gastric ulcer (GU)
Number of subjects: 0
Study 12741449 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients with ulcer-free gastritis
Number of subjects: 0
Study 12741449 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication in DU
Number of subjects: 0
Study 12741449 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication in GU
Number of subjects: 0
Study 12741449 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative controls
Number of subjects: 0
Study 10574587 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative AAA patients (postop-AAA)
Number of subjects: 18
Study 10574587 — intervention group
Group type: COMPARATOR
Intervention: Preoperative AAA patients (preop-AAA)
Number of subjects: 18
Study 10574587 — intervention group
Group type: COMPARATOR
Intervention: Age-matched healthy controls (AMC)
Number of subjects: 18
Study 8554016 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy (intravenous thrombolytic agents or urgent percutaneous transluminal coronary angioplasty)
Number of subjects: 20
Study 1320913 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg)
Number of subjects: 40
Study 1320913 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (3 mg/kg) plus dexamethasone (12 mg)
Number of subjects: 40
Study 1320913 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (up to 200 mg/24 h) plus dexamethasone (12 mg)
Number of subjects: 40
Study 1320913 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 40
Study 1320913 — intervention group
Group type: COMPARATOR
Intervention: Comparator groups
Number of subjects: 40
Study 6483068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 20
Study 6483068 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 20
Study 31174710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (various intensities)
Number of subjects: 602
Study 30391914 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusions of vancomycin (CIV)
Number of subjects: 200
Study 30391914 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusions of vancomycin (IIV)
Number of subjects: 200
Study 25782451 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 100
Study 25782451 — intervention group
Group type: COMPARATOR
Intervention: Post-operative patients (24-48 h after catheter ablation)
Number of subjects: 100
Study 25782451 — intervention group
Group type: COMPARATOR
Intervention: Followed-up patients (58.52 ± 36.00 days after catheter ablation)
Number of subjects: 100
Study 25156622 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (30 mg intraoperatively)
Number of subjects: 46
Study 25156622 — intervention group
Group type: COMPARATOR
Intervention: Rabbit anti-thymocyte globulin (multiple doses starting intraoperatively)
Number of subjects: 46
Study 21210862 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 kg/(calf × day) of concentrate)
Number of subjects: 36
Study 21210862 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted group (1 kg/(calf × day) of concentrate)
Number of subjects: 36
Study 21210862 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 21210862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 20180945 — intervention group
Group type: EXPERIMENTAL
Intervention: in‐tune fast music
Number of subjects: 75
Study 20180945 — intervention group
Group type: EXPERIMENTAL
Intervention: out‐of‐tune fast music
Number of subjects: 75
Study 20180945 — intervention group
Group type: COMPARATOR
Intervention: background music (various conditions)
Number of subjects: 75
Study 17914568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln/Gln genotype in CRC patients (18.0%)
Number of subjects: 300
Study 17914568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln/Gln genotype in well-differentiated grade CRC patients
Number of subjects: 300
Study 17914568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln/Gln genotype in lymph node metastasis (N1) CRC patients
Number of subjects: 300
Study 17914568 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls with no CRC (11.5%)
Number of subjects: 300
Study 16103688 — intervention group
Group type: EXPERIMENTAL
Intervention: rBet v 1 trimer
Number of subjects: 27
Study 16103688 — intervention group
Group type: EXPERIMENTAL
Intervention: rBet v 1 fragments
Number of subjects: 27
Study 16103688 — intervention group
Group type: COMPARATOR
Intervention: Placebo-aluminium hydroxide
Number of subjects: 27
Study 12097201 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine and lithium group (Li group) - lithium carbonate, 300 mg three times a day for 3 weeks starting on the day of radioiodine administration
Number of subjects: 350
Study 12097201 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine group (controls) - no lithium given
Number of subjects: 350
Study 9858319 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaseron (8 MIU every other day s.c.)
Number of subjects: 16
Study 9858319 — intervention group
Group type: COMPARATOR
Intervention: AVONEX (6 MIU single i.m. dose)
Number of subjects: 16
Study 7561225 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' knowledge of NSAID prices
Number of subjects: 95
Study 7561225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost consideration by physicians
Number of subjects: 95
Study 7561225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy price variation
Number of subjects: 95
Study 2236452 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 155
Study 2236452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 1011271 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback on rate and amplitude of tumescence
Number of subjects: 0
Study 1011271 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback techniques
Number of subjects: 0
Study 31794239 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Alcohol Approach‐Avoidance Training Task
Number of subjects: 28
Study 31794239 — intervention group
Group type: COMPARATOR
Intervention: Sham training condition
Number of subjects: 28
Study 29019297 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTI-SCRIPT intervention
Number of subjects: 196
Study 25682064 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate low-carbohydrate diet (M-LCD) for 3 months
Number of subjects: 76
Study 22503722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-group: 500 mg/d calcium
Number of subjects: 214
Study 22503722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca+MZ-group: 500 mg/d calcium + multivitamin tablet containing 15 mg/d zinc
Number of subjects: 214
Study 22503722 — intervention group
Group type: COMPARATOR
Intervention: C-group: multivitamin tablet without any minerals
Number of subjects: 214
Study 22503722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-group and Ca+MZ-group
Number of subjects: 214
Study 20435196 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1442
Study 20435196 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1442
Study 20435196 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 1442
Study 20435196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1442
Study 18469027 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling
Number of subjects: 366
Study 12905544 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-layer paste bandages
Number of subjects: 133
Study 12905544 — intervention group
Group type: COMPARATOR
Intervention: Four-layer bandages
Number of subjects: 133
Study 10681870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonifying the kidney with improving blood circulation
Number of subjects: 141
Study 10681870 — intervention group
Group type: COMPARATOR
Intervention: Tonifying the kidney alone
Number of subjects: 141
Study 8618250 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary alkalinization for 24 hours
Number of subjects: 10
Study 8618250 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose activated charcoal (six doses) and two doses of sorbitol over 24 hours
Number of subjects: 10
Study 8618250 — intervention group
Group type: COMPARATOR
Intervention: Control (no interventions)
Number of subjects: 10
Study 1741720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat (LF) group
Number of subjects: 24
Study 1741720 — intervention group
Group type: COMPARATOR
Intervention: High fat (HF) group
Number of subjects: 24
Study 6289856 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with diazepam 5 mg rectally and atropine 0.3‐0.4 mg sublingually (Group A)
Number of subjects: 14
Study 6289856 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal combination of diazepam 0.5 mg kg‐1, morphine 0.15 mg kg‐1 and hyoscine 0.01 mg kg‐1 (Group B)
Number of subjects: 14
Study 30356311 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured discussion condition with instructor guidance
Number of subjects: 99
Study 30356311 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpolated testing condition with test questions throughout the video
Number of subjects: 99
Study 30356311 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition of watching the video as in current practice
Number of subjects: 99
Study 30356311 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous discussion condition without guidelines
Number of subjects: 99
Study 26879200 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) 50 mg weekly for up to 8 years
Number of subjects: 117
Study 26879200 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) 50 mg weekly for up to 8 years with vitamin D3 (5600 IU) and calcium supplementation
Number of subjects: 117
Study 24604584 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT-HI
Number of subjects: 45
Study 24604584 — intervention group
Group type: COMPARATOR
Intervention: IMT-E
Number of subjects: 45
Study 21881529 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second rest interval
Number of subjects: 30
Study 21881529 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-second rest interval
Number of subjects: 30
Study 21881529 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-second rest interval
Number of subjects: 30
Study 20206540 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimised perfusion circuit (MPC)
Number of subjects: 291
Study 20206540 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (CCPB)
Number of subjects: 291
Study 17846812 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate Spheroidal Oral Drug Absorption System (MPH-SODAS)
Number of subjects: 62
Study 15902741 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH and lactulose
Number of subjects: 48
Study 15902741 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 14533282 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based training after initial hospital walking training (n = 14)
Number of subjects: 26
Study 14533282 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 26
Study 10390392 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized uridine-5'-triphosphate (UTP) 5 mg/ml, 3.5 ml
Number of subjects: 12
Study 10390392 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (0.12% saline, 3.5 ml)
Number of subjects: 12
Study 9071082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (2.5 mg in 3 ml)
Number of subjects: 30
Study 9071082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized metaproterenol (15 mg in 3 ml)
Number of subjects: 30
Study 9071082 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline 3 ml (control group)
Number of subjects: 30
Study 1864451 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/day Imedeen for 90 days
Number of subjects: 10
Study 1864451 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 90 days
Number of subjects: 10
Study 6401426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nitroglycerine (NTG) administered 1 min before induction of anaesthesia
Number of subjects: 35
Study 6401426 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NTG)
Number of subjects: 35
Study 6401426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NTG and Control)
Number of subjects: 35
Study 31421659 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized MgSO4
Number of subjects: 33
Study 31421659 — intervention group
Group type: COMPARATOR
Intervention: Nebulized ipratropium bromide/fenoterol
Number of subjects: 33
Study 31421659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33